Gilead Says Trodelvy 'Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer'
Portfolio Pulse from Benzinga Newsdesk
Gilead announced that Trodelvy, the first Trop-2-directed ADC, demonstrated a durable overall survival advantage in pre-treated HR+/HER2- metastatic breast cancer patients. The Phase 3 TROPiCS-02 study showed a 3.3-month improvement in median overall survival compared to chemotherapy.
June 05, 2023 | 4:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gilead's Trodelvy demonstrated a significant survival advantage in pre-treated HR+/HER2- metastatic breast cancer patients, potentially boosting the company's oncology portfolio.
The positive results from the Phase 3 TROPiCS-02 study indicate that Trodelvy has a strong potential to become a leading treatment option for HR+/HER2- metastatic breast cancer patients. This could lead to increased revenues for Gilead and strengthen its position in the oncology market, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100